Literature DB >> 14568411

In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel.

Mitsunaga Konishi1, Yasuhiko Tabata, Masatoshi Kariya, Ayako Suzuki, Masaki Mandai, Kanako Nanbu, Kenji Takakura, Shingo Fujii.   

Abstract

This paper is an investigation to achieve the in vivo controlled release of cisplatin (CDDP) from a biodegradable hydrogel. Hydrogels with different water contents were prepared through the chemical crosslinking of gelatin by various concentrations of glutaraldehyde. The gelatin hydrogel incorporating CDDP (CDDP-hydrogel) was prepared by allowing CDDP aqueous solution to sorb into the freeze-dried hydrogel. Irrespective of the hydrogel water content, approximately 10-30% of incorporated CDDP was released from the hydrogel in phosphate-buffered saline solution (PBS) at 37 degrees C within the initial 6 h, while little release was observed thereafter. The amount of CDDP released initially decreased with an increase in the time period of CDDP sorption. When intratumorally applied into Meth-AR-1 tumor-bearing mice, CDDP-hydrogel suppressed in vivo tumor growth to a significantly higher extent than free CDDP at the same dose. The survival rate was significantly higher by the application of CDDP-hydrogel of 40 microg CDDP. The CDDP concentration in the tumor tissue was maintained at a higher level for a longer time period than that of free CDDP. However, no problematic change in the mouse body and blood biochemical parameters was observed on the application of the CDDP-hydrogel. The time course of in vivo CDDP retention was in a good accordance with that of hydrogel remaining. Larger CDDP release was observed from the front surface of hydrogel onto which free CDDP was sorbed, than the back surface of hydrogel. These findings demonstrate that the controlled release of CDDP was based on biodegradation of the hydrogel carrier, but not simple diffusion of CDDP. It is possible that the CDDP molecules immobilized in the gelatin hydrogel were released from the hydrogel only when the hydrogel was degraded to generate some water-soluble gelatin fragments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568411     DOI: 10.1016/s0168-3659(03)00364-x

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  12 in total

1.  Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma.

Authors:  Tetsuya Toyama; Norihisa Nitta; Shinichi Ohta; Toyohiko Tanaka; Yukihiro Nagatani; Masashi Takahashi; Kiyoshi Murata; Hisanori Shiomi; Shigeyuki Naka; Yoshimasa Kurumi; Tohru Tani; Yasuhiko Tabata
Journal:  Jpn J Radiol       Date:  2011-12-17       Impact factor: 2.374

2.  Regional radiochemotherapy using in situ hydrogel.

Authors:  Ali Azhdarinia; David J Yang; Dong-Fang Yu; Richard Mendez; Changsok Oh; Saady Kohanim; Jerry Bryant; E Edmund Kim
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

Review 3.  Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers.

Authors:  Jesse B Wolinsky; Yolonda L Colson; Mark W Grinstaff
Journal:  J Control Release       Date:  2011-12-01       Impact factor: 9.776

4.  Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

Authors:  Tae Heung Kang; Jin Hyup Lee; Chung Kil Song; Hee Dong Han; Byung Cheol Shin; Sara I Pai; Chien-Fu Hung; Cornelia Trimble; Jong-Seok Lim; Tae Woo Kim; T-C Wu
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

5.  Reversible maleimide-thiol adducts yield glutathione-sensitive poly(ethylene glycol)-heparin hydrogels.

Authors:  Aaron D Baldwin; Kristi L Kiick
Journal:  Polym Chem       Date:  2013-01-07       Impact factor: 5.582

6.  Comparing human peritoneal fluid and phosphate-buffered saline for drug delivery: do we need bio-relevant media?

Authors:  Prabhat Bhusal; Jamie Lee Rahiri; Bruce Sua; Jessica E McDonald; Mahima Bansal; Sara Hanning; Manisha Sharma; Kaushik Chandramouli; Jeff Harrison; Georgina Procter; Gavin Andrews; David S Jones; Andrew G Hill; Darren Svirskis
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

7.  Cisplatin tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.

Authors:  Ariella Shikanov; Sergey Shikanov; Boris Vaisman; Jacob Golenser; Abraham J Domb
Journal:  Chemother Res Pract       Date:  2011-02-27

Review 8.  Nanotechnology-based drug delivery systems for treatment of oral cancer: a review.

Authors:  Giovana Calixto; Jéssica Bernegossi; Bruno Fonseca-Santos; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2014-08-08

9.  Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity.

Authors:  Soo Hong Seo; Hee Dong Han; Kyung Hee Noh; Tae Woo Kim; Sang Wook Son
Journal:  Clin Exp Metastasis       Date:  2008-12-14       Impact factor: 4.510

10.  Poly Lactic-Co-Glycolic Acid- (PLGA-) Loaded Nanoformulation of Cisplatin as a Therapeutic Approach for Breast Cancers.

Authors:  Saad Alkahtani; Saud Alarifi; Gadah Albasher; Mohammed Al-Zharani; Nada H Aljarba; Mohammed H Almarzoug; Norah M Alhoshani; Norah S Al-Johani; Hani Alothaid; Abdullah A Alkahtane
Journal:  Oxid Med Cell Longev       Date:  2021-06-28       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.